{"id":"NCT00436553","sponsor":"Novartis","briefTitle":"Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization","officialTitle":"A 24-month Randomized, Double-masked, Controlled, Multicenter, Phase IIIB Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-02","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2007-02-19","resultsPosted":"2011-04-19","lastUpdate":"2011-04-19"},"enrollment":321,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Macular Degeneration","Choroidal Neovascularization"],"interventions":[{"type":"DRUG","name":"Verteporfin Photodynamic Therapy","otherNames":["Visudyne"]},{"type":"DRUG","name":"Ranibizumab","otherNames":["Lucentis"]},{"type":"DRUG","name":"Verteporfin Placebo","otherNames":[]},{"type":"DRUG","name":"Ranibizumab Placebo","otherNames":[]}],"arms":[{"label":"Verteporfin With Standard Fluence Rate Plus Ranibizumab","type":"EXPERIMENTAL"},{"label":"Ranibizumab Monotherapy","type":"ACTIVE_COMPARATOR"},{"label":"Verteporfin With Reduced Fluence Rate Plus Ranibizumab","type":"EXPERIMENTAL"}],"summary":"This study evaluated the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity and anatomic outcomes compared to ranibizumab monotherapy and the durability of response observed in patients with choroidal neovascularization secondary to age-related macular degeneration.","primaryOutcome":{"measure":"Mean Change From Baseline in Best-corrected Visual Acuity (BCVA) of the Study Eye at Month 12","timeFrame":"Baseline and Month 12","effectByArm":[{"arm":"Verteporfin SF + Ranibizumab","deltaMin":53.7,"sd":13.52},{"arm":"Verteporfin RF + Ranibizumab","deltaMin":54.6,"sd":12.78},{"arm":"Ranibizumab Monotherapy","deltaMin":54.8,"sd":13.55}],"pValues":[]},"eligibility":{"minAge":"50 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":2},"locations":{"siteCount":43,"countries":["United States","Canada"]},"refs":{"pmids":["22444829"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":32,"n":104},"commonTop":["Eye pain (Study eye)","Conjunctival haemorrhage (Study eye)","Hypertension","Nasopharyngitis","Upper respiratory tract infection"]}}